Ingestible light source for intragastric antibacterial phototherapy: a device safety study on a minipig model
-
Published:2022-11-15
Issue:3
Volume:22
Page:535-547
-
ISSN:1474-9092
-
Container-title:Photochemical & Photobiological Sciences
-
language:en
-
Short-container-title:Photochem Photobiol Sci
Author:
Orsini Barbara, Busechian Sara, Faraoni Paola, Burchielli Silvia, Maggi Giulia, Rogai Francesca, Gnerucci Alessio, Tortoli Paolo, Milani Stefano, Treghini Chiara, Dell’Accio Alfonso, Romano GiovanniORCID, Rueca Fabrizio, Fusi Franco
Abstract
AbstractHelicobacter pylori gastric infections are among the most diffused worldwide, suffering from a rising rate of antibiotic resistance. In this context, some of the authors have previously designed an ingestible device in the form of a luminous capsule to perform antibacterial photodynamic inactivation in the stomach. In this study, the light-emitting capsules were tested to verify the safety of use prior to perform clinical efficacy studies. First, laboratory tests measured the capsule temperature while in function and verified its chemical resistance in conditions mimicking the gastric and gut environments. Second, safety tests in a healthy minipig model were designed and completed, to verify both the capsule integrity and the absence of side effects, associated with its illumination and transit throughout the gastrointestinal tract. To this aim, a capsule administration protocol was defined considering a total of 6 animals with n = 2 treated with 8 capsules, n = 2 treated with 16 capsules and n = 2 controls with no capsule administration. Endoscopies were performed in sedated conditions before–after every capsule administration. Biopsies were taken from the corpus and antrum regions, while the gastric cavity temperature was monitored during illumination. The bench tests confirmed a very good chemical resistance and a moderate (about 3 °C) heating of the capsules. The animal trials showed no significant effects on the gastric wall tissues, both visually and histologically, accompanied with overall good animal tolerance to the treatment. The integrity of the administered capsules was verified as well. These encouraging results pose the basis for the definition of successive trials at the clinical level.
Graphical abstract
Funder
Fondazione Cassa di Risparmio di Firenze Regione Toscana Università degli Studi di Firenze
Publisher
Springer Science and Business Media LLC
Subject
Physical and Theoretical Chemistry
Reference40 articles.
1. International Agency for Research on Cancer, World Health organization. (1994). Schistosomes, liver flukes and Helicobacter pylori. In: AIRC Monographs on Evaluation of Carcinogenesis Risks to Humans. IARC Press, Volume 60, p. 177. 2. Gerrits, M. M., van Vliet, A. H. M., Kuipers, E. J., & Kusters, J. G. (2006). Helicobacter pylori and antimicrobial resistance: Molecular mechanisms and clinical implications. Lancet Infection Disease, 6, 699–709. 3. Dunn, B. E., Cohen, H., & Blaser, J. (1997). Helicobacter pylori. Clinical Microbiology Reviews, 10, 720–741. 4. Sugano, K., Tack, J., Kuipers, E. J., Graham, D. Y., El-Omar, E. M., Miura, S., Haruma, K., Asaka, M., Uemura, N., Malfertheiner, P., & Faculty Members of Kyoto Global Consensus Conference. (2015). Kyoto global consensus report on Helicobacter pylori gastritis. Gut, 64, 1353–1367. https://doi.org/10.1136/gutjnl-2015-309252 5. Fasciana, T., Capra, G., Cala’, C., Zambuto, S., Mascarella, C., Colomba, C., Di Carlo, P., & Giammanco, A. (2017). Helicobacter pylori and Epstein–Barr co-infection in gastric disease. Pharmacology Online, 4, 73–82.
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|